pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Innovent Biologics Inc · news · pharmadog
← back to Innovent Biologics Inc
News mentioning Innovent Biologics Inc
21
stories
2d
J&J bets $2.2B on Ollin’s vision loss drug
biopharma dive
2d
J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
biospace
2d
J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
fiercebiotech
11d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
13d
At ASH, drugmakers to showcase early data for three-pronged cancer therapies
biopharma dive
26d
ESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 win
fiercebiotech
27d
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals
fiercebiotech
Sep 24, 26
Lilly’s latest China drug deal; Immunovant’s setback in lupus
biopharma dive
Aug 31, 26
China poses increasing security risk as US biotech innovation edge erodes
biospace
Aug 10, 26
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win
endpoints
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 15, 26
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
biopharma dive
Jul 14, 26
In latest deal, Innovent seeds Spero's future beyond GSK-owned antibiotic
endpoints
Jun 30, 26
These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.
biopharma dive
Jun 26, 26
At BIO, tension over China biotech deal regulation looms
biopharma dive
Jun 5, 26
Innovent declares Phase 3 success for ADC that attracted huge Takeda deal
endpoints
Jun 4, 26
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
biopharma dive
Jun 3, 26
House bill aims to crack down on China biotech deals
biopharma dive
May 29, 26
STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
stat
May 29, 26
Pfizer, Innovent strike $10B cancer drug deal
biopharma dive
May 29, 26
Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs
endpoints